CADTH | Evidence Driven
CADTH | Evidence Driven

Halaven for Metastatic Breast Cancer - Details

Details

Files
Generic Name:
Eribulin Mesylate
Project Status:
Complete
Therapeutic Area:
Metastatic Breast Cancer
Manufacturer:
Eisai Ltd.
Brand Name:
Halaven
Project Line:
Reimbursement Review
Project Number:
PC0005-000
Strength:
1mg per 2 mL vial
Tumour Type:
Breast
Indications:
Metastatic Breast Cancer
Review Status:
Complete
Sponsor:
Eisai Ltd.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request *Revised at Submitter's request:
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane administered in either the adjuvant or metastatic setting.
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Eribulin (Halaven) for Metastatic Breast - pERC Final Recommendation Final Recommendation August 2, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - Final Clinical Guidance Report Guidance Reports August 2, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - Final Economic Guidance Report Guidance Reports August 2, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - pERC Initial Recommendation Initial Recommendation June 1, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - PAG Feedback on Initial Recommendation Feedback August 2, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - Manufacturer (Eisai) Feedback on Initial Recommendation Feedback August 2, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - Patient Advocacy Group (CBCN) COI Declarations Feedback August 2, 2012 View PDF
Eribulin (Halaven) for Metastatic Breast Cancer - Patient Advocacy Group (CCSN) COI Declarations Feedback August 2, 2012 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 20, 2012